
Lilly’s Psychedelics Bet Could Kickstart a Pharma M&A Wave
Eli Lilly’s $2.8 billion acquisition of AtaiBeckley, which includes the fast‑acting 5‑MeO‑DMT program BPL‑003 with phase 2b data for treatment‑resistant depression, underscores growing momentum for psychedelic medicines among Big Pharma and could spur further M&A as investors gain confidence and regulatory signals improve; however, logistical and delivery challenges remain, shaping the type of assets likely to be acquired (favoring programs with solid top‑line data and scalable pathways) and keeping an eye on potential targets like GH Research.













